Literature DB >> 10233409

Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside.

J Braess1, C Wegendt, M Feuring-Buske, J Riggert, W Kern, W Hiddemann, E Schleyer.   

Abstract

Different metabolites of cytosine arabinoside (AraC) contribute to its cytotoxicity including incorporation of AraCTP into DNA, the incorporation of AraUMP into RNA, inhibition of polymerase alpha and beta (AraCMP/CTP), an impairment of repair mechanisms (AraCTP), alterations of phospholipid metabolism (AraCDP-choline), a direct membrane interaction (AraC), the alteration of signal transduction pathways (AraCDP-choline, AraCTP) and the induction of apoptosis. Since little is known about the potential differences in AraC metabolism between leukaemic blasts and normal haemopoietic progenitor cells, the formation of all known AraC metabolites was determined in bone marrow samples from patients with acute myeloid leukaemia (AML), healthy volunteers and specimens of cellsorted CD34+ haemopoietic stem cells. Highly significant differences were found for phosphorylated AraC metabolites (AraCMP, -CDP, -CTP, AraUMP) between AML and normal mononuclear bone marrow (ng/107 cells respectively 1.30 v 2.66; 2.65 v 7.50; 33.68 v 99.0; 1.18 v 5.70). The highest differences were found for formation of AraCDP-choline (3.75 v 12.86) which might be relevant for the high efficacy of high-dose AraC regimens. In contrast, no differences were found in the deamination product AraU (2.01 v 2.91). Only minute amounts of phosphorylated AraU derivatives were detected, providing an explanation for the lacking contribution of AraU to cytosine arabinoside cytotoxicity. Results in normal CD34+ haemopoietic stem cells did not differ significantly from normal bone marrow mononuclear cells and therefore justify their use as a surrogate in determining AraC-induced haematotoxicity. These data suggest a metabolic basis for the relative selectivity of AraC cytotoxicity for AML blasts and provide a means to determine the role of different metabolites and their related mechanism of action for overall AraC cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233409

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

Review 2.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 3.  An overview of the vaccinia virus infectome: a survey of the proteins of the poxvirus-infected cell.

Authors:  Wayne Chou; Tuan Ngo; Paul D Gershon
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

4.  Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Authors:  Reda Z Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J Engelke; Mikkael A Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

5.  Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.

Authors:  J M Sargent; A W Elgie; C J Williamson; G M Lewandowicz; C G Taylor
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.